HDAC6 and Miyoshi myopathy: Consequently, a selective HDAC6 inhibitor (ACY-241) enhanced pomalidomide anti-tumor response in MM [39] and ricolinostat (ACY-1215) is in test in combination with BTZ and dexamethasone for relapsed or refractory MM [40].